Allison Ramsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allison Ramsey has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Syed Shahzad Mustafa
Rochester Regional Health, Rochester, New York; University of Rochester School of Medicine & Dentistry, Rochester, New York
13 shared publications S. Shahzad Mustafa
7 shared publicationsKarthik Vadamalai
Mercy Hospital, Springfield, MO
4 shared publications- Mary L. Staicu
Rochester Regional Health, Rochester, NY
3 shared publications Ana Maria Copaescu
2 shared publicationsBenjamin Mervak
Department of Radiology, Michigan Medicine, Ann Arbor, Mich
2 shared publications
Latest Publications
- 5 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (6) , 1292-1294
Allergic Diseases During Pregnancy: Reassuring Uncertainty
- 5 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (6) , 1292-1294
Allergic Diseases During Pregnancy: Reassuring Uncertainty
- 2 February 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (2) , 127-128
Safely subtracting sulfa allergy: It's time
- 2 February 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 136 (2) , 127-128
Safely subtracting sulfa allergy: It's time
- 31 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (5) , 1007-1013
Novel Uses of Digital Health and the Electronic Medical Record in Drug Allergy
- 31 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (5) , 1007-1013
Novel Uses of Digital Health and the Electronic Medical Record in Drug Allergy
- Open Access
- 27 December 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Combination therapy with TNF inhibitors plus biologics targeting type 2 inflammatory conditions in patients with rheumatoid arthritis: a case series
Objectives: Patients with RA treated with TNF inhibitors (TNFis) may experience type 2 inflammatory conditions such as asthma, atopic dermatitis or urticaria. Multiple biologic agents targeting type 2 inflammation are available. Combination biologic therapy targeting types 1 and 2 inflammation is not well described. We present a series of patients on a combination TNFi and biologic agent targeting type 2 inflammation. Methods: A retrospective case series of RA patients on TNFi receiving a biologic agent for type 2 inflammatory conditions was compiled. Descriptive data, duration of biologic use, incident bacterial infections and corticosteroid used 6 months before and after combination biologic agent use was collected. Results: Twelve patients were included. The mean overlap of combination biologic therapy was 83.7 weeks (95% CI 56.0, 111.4) and the median was 92.6 weeks [interquartile range (IQR) 36.4–109.8]. The mean corticosteroid cumulative dose 6 months prior to dual biologic agents was 463 mg prednisone equivalent (95% CI 131, 795) and the median was 265 mg (IQR 75–570). The mean corticosteroid cumulative dose 6 months after dual biologic agents was 241 mg prednisone equivalent (95% CI −21, 503) and the median was 0 mg (IQR 0–275). Six bacterial infections occurred prior to combination biologic therapy compared with five after initiating dual biologics. Conclusion: This case series demonstrates that adding a second biologic agent to target type 2 inflammatory conditions in RA patients on TNFi did not increase incident bacterial infections and may decrease corticosteroid use.
- 27 December 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1)
Open AccessCombination therapy with TNF inhibitors plus biologics targeting type 2 inflammatory conditions in patients with rheumatoid arthritis: a case series
Objectives: Patients with RA treated with TNF inhibitors (TNFis) may experience type 2 inflammatory conditions such as asthma, atopic dermatitis or urticaria. Multiple biologic agents targeting type 2 inflammation are available. Combination biologic therapy targeting types 1 and 2 inflammation is not well described. We present a series of patients on a combination TNFi and biologic agent targeting type 2 inflammation. Methods: A retrospective case series of RA patients on TNFi receiving a biologic agent for type 2 inflammatory conditions was compiled. Descriptive data, duration of biologic use, incident bacterial infections and corticosteroid used 6 months before and after combination biologic agent use was collected. Results: Twelve patients were included. The mean overlap of combination biologic therapy was 83.7 weeks (95% CI 56.0, 111.4) and the median was 92.6 weeks [interquartile range (IQR) 36.4–109.8]. The mean corticosteroid cumulative dose 6 months prior to dual biologic agents was 463 mg prednisone equivalent (95% CI 131, 795) and the median was 265 mg (IQR 75–570). The mean corticosteroid cumulative dose 6 months after dual biologic agents was 241 mg prednisone equivalent (95% CI −21, 503) and the median was 0 mg (IQR 0–275). Six bacterial infections occurred prior to combination biologic therapy compared with five after initiating dual biologics. Conclusion: This case series demonstrates that adding a second biologic agent to target type 2 inflammatory conditions in RA patients on TNFi did not increase incident bacterial infections and may decrease corticosteroid use.
- Open Access
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Recommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Open AccessRecommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1029-1047
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement From the American College of Radiology and the American Academy of Allergy, Asthma, & Immunology
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1029-1047
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement From the American College of Radiology and the American Academy of Allergy, Asthma, & Immunology
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1027-1028
Drug Allergy: Change Is the Only Constant
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1027-1028
Drug Allergy: Change Is the Only Constant
- 1 May 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (2) , e240100
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology
Key outcomes from a multidisciplinary task force on hypersensitivity reactions to iodinated contrast media include recommendations to document reactions thoroughly in the electronic health record, including symptoms and the specific inciting agent, and a discussion of varying strategies for avoidance of repeat acute hypersensitivity reactions to iodinated contrast media according to the severity of the index reaction; importantly, no corticosteroid premedication is generally recommended for patients with a prior mild acute hypersensitivity reaction.
- 1 May 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (2) , e240100
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology
Key outcomes from a multidisciplinary task force on hypersensitivity reactions to iodinated contrast media include recommendations to document reactions thoroughly in the electronic health record, including symptoms and the specific inciting agent, and a discussion of varying strategies for avoidance of repeat acute hypersensitivity reactions to iodinated contrast media according to the severity of the index reaction; importantly, no corticosteroid premedication is generally recommended for patients with a prior mild acute hypersensitivity reaction.
- 29 January 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 1-12
Hypersensitivity Reactions to Anticonvulsants
Background Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies. Objective This review article aims to describe the types of hypersensitivity reactions reported with antiepileptics with emphasis on delayed hypersensitivity reactions, as these can be life-threatening. Methods Online databases including PubMed and Cochrane were searched, from the inception of the literature to 5/10/24. Studies focusing on hypersensitivity reactions to antiepileptics were reviewed. Case reports, case series, observational studies, and clinical trials were included. Abstracts and studies published in languages other than English were not included. Results Immediate reactions can occur with antiepileptics however the incidence is lower than that of delayed hypersensitivity reactions. Delayed hypersensitivity reactions include benign rash as well as severe cutaneous adverse reactions. Acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, Steven Johnson syndrome, and toxic epidermal necrolysis are discussed in detail in this review. We focused on pathogenesis, genetic predisposition, clinical presentation, treatment, and prognosis. Conclusion Severe cutaneous adverse reactions can be lethal. It is important to make the correct diagnosis and treat patients accordingly. More studies comparing therapeutic options head-to-head are needed.
- 29 January 2025
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 25 (1) , 1-12
Hypersensitivity Reactions to Anticonvulsants
Background Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies. Objective This review article aims to describe the types of hypersensitivity reactions reported with antiepileptics with emphasis on delayed hypersensitivity reactions, as these can be life-threatening. Methods Online databases including PubMed and Cochrane were searched, from the inception of the literature to 5/10/24. Studies focusing on hypersensitivity reactions to antiepileptics were reviewed. Case reports, case series, observational studies, and clinical trials were included. Abstracts and studies published in languages other than English were not included. Results Immediate reactions can occur with antiepileptics however the incidence is lower than that of delayed hypersensitivity reactions. Delayed hypersensitivity reactions include benign rash as well as severe cutaneous adverse reactions. Acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, Steven Johnson syndrome, and toxic epidermal necrolysis are discussed in detail in this review. We focused on pathogenesis, genetic predisposition, clinical presentation, treatment, and prognosis. Conclusion Severe cutaneous adverse reactions can be lethal. It is important to make the correct diagnosis and treat patients accordingly. More studies comparing therapeutic options head-to-head are needed.